SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.
Sage Therapeutics verfehlte mit den Q1-Zahlen zwar die Prognosen, allerdings wurden die Investoren zuletzt bei diversen Konferenzen vom innovativen Präparat ZULRESSO überzeugt. Eingeführt wird dieses voraussichtlich Ende Juni. Dieses dient zur Behandlung von Störungen des zentralen Nervensystems, insbesondere von postpartalen Depressionen. Wedbush wird angesichts der starken Wachstumsaussichten...
The average of price targets set by Wall Street analysts indicates a potential upside of 152.4% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly...
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced...
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.
Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesnt...
